Octapeptin C4 Induces Less Resistance and Novel Mutations in an Epidemic Carbapenemase-producing *Klebsiella pneumoniae* ST258 Clinical Isolate Compared to Polymyxins

Miranda E. Pitt^a, Minh Duc Cao^a, Mark S. Butler^a, Soumya Ramu^a, Devika Ganesamoorthy^a, Mark A. T. Blaskovich^a, Lachlan J. M. Coin^{a#} and Matthew A. Cooper^{a#}

^aInstitute for Molecular Bioscience, The University of Queensland, Brisbane, Australia

Running Title: Induced Polymyxin and Octapeptin C4 Resistance

Address correspondence to authors: Matthew Cooper (m.cooper@uq.edu.au) & Lachlan Coin (l.coin@imb.uq.edu.au)

ABSTRACT

Polymyxin B and E (colistin) have been pivotal in the treatment of extensively drug-resistant (XDR) Gram-negative bacterial infections, with increasing use over the past decade. Unfortunately, resistance to these antibiotics is rapidly emerging. The structurally-related octapeptin C4 (OctC4) has shown significant potency against XDR bacteria, including against polymyxin-resistant (Pmx-R) strains, but its mode of action remains undefined. We sought to compare and contrast the acquisition of XDR *Klebsiella pneumoniae* (ST258) resistance *in vitro* with all three lipopeptides to help elucidate the mode of action of the drugs and potential mechanisms of resistance evolution. Strikingly, 20 days of exposure to the polymyxins resulted in a dramatic (1000-fold) increase in the minimum inhibitory concentration (MIC) for the polymyxins, reflecting the evolution of resistance seen in clinical isolates, whereas for OctC4 only a 4-fold increase was witnessed. There was no cross-resistance observed between the polymyxin- and octapeptin-induced resistant strains. Sequencing revealed previously known gene alterations for polymyxin resistance, including *rrb*, *mgrB*, *pmrB*, *phoPQ* and *yciM*, and novel mutations in *qseC*. In contrast, mutations in *mldF* and *pqiB*, genes related to phospholipid transport, were found in octapeptin-resistant isolates. Mutation effects were validated via complementation assays. These genetic variations were reflected in phenotypic changes to lipid A. Pmx-R isolates increased 4-amino-4-deoxy-arabinose fortification to phosphate groups of lipid A, whereas OctC4 induced strains harbored a higher abundance of hydroxymyristate and palmitoylate. The results reveal a differing mode of action compared to polymyxins which provides hope for future therapeutics to combat the increasingly threat of XDR bacteria.

Keywords: Polymyxins, Octapeptin C4, Extensively drug-resistant, *Klebsiella pneumoniae*, Lipid A, Cross-resistance

INTRODUCTION

Infections by extensively drug-resistant (XDR) bacteria are an increasing concern due to the lack of effective antibiotics, thereby resulting in high mortality (1, 2). Common therapeutic interventions include fosfomycin, tigecycline and polymyxins (2-4). However, the effectiveness of these therapies is short lived due to plasmid-encoded resistance (fosfomycin (4), polymyxin (5)) and rapid acquisition of resistance through mutation (fosfomycin (6), tigecycline (7) and polymyxin (8, 9)). New antibiotics with the capacity to ablate these XDR bacteria are urgently desired.

Octapeptins are structurally similar to the polymyxins, with both lipopeptide classes consisting of a cyclic heptapeptide ring and linear tail capped with a fatty acid, containing multiple positively charged diaminobutyric acid (Dab) residues (10-12) (Fig. 1). Studies on the polymyxins have shown that these Dab residues are critical for interactions with the basal component of lipopolysaccharide (LPS), lipid A. The mode of action involves the initial binding to lipid A, displacement of magnesium (Mg^{2+}) and calcium (Ca^{2+}), permeabilization of the outer and inner membrane, leakage of cytoplasmic contents and subsequent cell death, however, the exact mechanism is yet to be discerned (13, 14). The phosphate groups on lipid A are modified during polymyxin resistance with 4-amino-4-deoxy-arabinose (Ara4N) and/ or phosphoethanolamine (pEtN) in order to stabilise the outer membrane. This reduces polymyxin binding by removing the negative phosphate that attracts the cationic Dab residues (15, 16). Constitutive up-regulation of this pathway is achieved through chromosomal variations in the two-component regulatory systems (TCS) *crrAB*, *pmrAB*, *phoPQ* and the negative regulator *mgrB* in *Klebsiella pneumoniae* (8, 9, 17). These modifications perturb the electrostatic interaction between lipid A and polymyxins to negate the infiltration of this antibiotic class. The structurally similar octapeptins

retain most of the key binding motifs, and might be expected to employ a similar mode of action. The most significant structural difference between the polymyxins and octapeptins is a truncated linear exocyclic peptide (1 residue instead of three) linked to a β -hydroxy-fatty acid (instead of an alkyl fatty acid) in the octapeptins (10-12). More minor variations include L-Dab to D-Dab and L-Thr to L-Leu substitutions. Loss of the fatty acid tail component has been shown to attenuate activity in polymyxins (18). Despite their similarity, prior research has revealed octapeptins retain the ability to kill Pmx-R bacteria, inferring an alternative mode of action (10). In addition, some octapeptins have broad spectrum activity with potency against Gram-positive bacteria, fungi and protozoa (19, 20).

We have recently reported the first synthesis of Octapeptin C4 (OctC4) (10) and Octapeptin A3 (21), followed by detailed biological characterisation of OctC4 that demonstrates its potential as a new ‘last resort’ antibiotic to treat serious extensively drug-resistant Gram-negative infections. (22). In view of the limited understanding of the mechanism by which octapeptins target bacteria, we sort to investigate the differences driving development of OctC4 and polymyxin resistance at a genetic level. Two studies have previously investigated the acquisition of resistance towards octapeptins. One was performed using EM49 (a mixture of octapeptin classes A and B) which exhibited no increase in resistance after 10 passages for *Pseudomonas aeruginosa*, *Escherichia coli*, *Staphylococcus aureus* and *Candida albicans* (23). The other investigated lipid A modifications in *P. aeruginosa* isolates resistant to OctC4 obtained from a subculture surviving a single overnight treatment at 2 or 32 μ g/ml.

The ST258 lineage of *K. pneumoniae* is endemic in numerous regions in the world and commonly involved in outbreaks (24-27). These isolates pose as a major threat due to frequently harboring carbapenem resistance, predominantly facilitated via *blaKPC* genes encoded on plasmids (25, 28). We have previously used whole genome sequencing to investigate the acquisition of resistance to polymyxin in an endemic lineage of *K. pneumoniae*, ST258, isolated from a Greek hospital (24). We selected one of these isolates which is susceptible to polymyxin and OctC4, but otherwise highly resistant (*aac(6')Ib*, *aac(6')Ib-cr*, *aph(3')-Ia*, *aph(3'')-Ib*, *aph(6)-Id*, *blaKPC-2*, *blaLEN-12*, *blaOXA-9*, *blaTEM-1B*, *fosA*, *oqxAB*, *sul2*, *tet(A)*, *dfrA14* positive), for resistance induction experiments. This strain is representative of the type of pathogens for which a 'last resort' antibiotic is employed, and one where high levels of clinical resistance to polymyxins have already been well characterised at a genetic level (24). The resistance induction experiments were followed by characterization of antibiotic susceptibility, whole genome sequencing, and analysis of lipid A composition. This research has uncovered significant differences in the development of resistance induced by the two classes of antibiotics, both in the level of resistance created and in the underlying genetic mutations. The results provide strong support for further development of the octapeptins as potential last-resort therapeutics.

RESULTS

Rapid resistance acquisition for polymyxins dissimilar to OctC4. Forced evolution on XDR *K.*

pneumoniae was monitored over a 20 day time course, with six replicates exposed to increasing concentrations of either polymyxin B (PMB), polymyxin E (colistin, CST) and OctC4. Significant variability was observed between polymyxins and OctC4 (Fig. 2D). Initially, an MIC of 0.125 µg/ml was measured for both CST and PMB. The majority of replicates treated with the polymyxins had a clinical resistance phenotype of >2 µg/ml by day 10 (Fig. 2A and B). At some point, every replicate had a dramatic and rapid escalation in MIC to >64 µg/ml, generally over ≤5 days. The timing for the drastic increase varied between replicates, and appeared dependent on whether the replicate could tolerate 0.5 µg/ml, with a steep escalation from the day that resistance level was exceeded. In sharp contrast, OctC4 resistance progressed steadily over the 20 days (Fig. 2C) with only a 4-fold (initial MIC: 8 µg/ml) overall increase compared to a ≥1000-fold increase for the polymyxins (Fig. 2E). The trend for a gradual increase in OctC4 resistance was consistent amongst replicates. The induced resistance appeared to be stable after five additional passages without antibiotic exposure for polymyxins. The extent of growth in wells containing either 32 or 16 µg/ml started to diminish for OctC4-induced isolates during the last passages.

Lack of cross-reactivity and reduction of resistance in OctC4 induced isolates. Day 20 isolate

MICs were determined against a broad array of antibiotic classes to evaluate if acquired resistance conferred cross-resistance, or resulted in regained susceptibility (Table 1). Remarkably, no cross-reactivity was apparent between polymyxins and OctC4. Non-susceptibility towards amoxicillin, aztreonam, ceftriaxone, ciprofloxacin, piperacillin and trimethoprim was ubiquitous amongst treatment groups. Chloramphenicol resistance was observed in the initial isolate but was diminished in the majority of replicates over the time course for all three antibiotics. In some

instances, cefepime susceptibility was restored (replicates OctC4_3, OctC4_4 and OctC4_6). These replicates also regained susceptibility to meropenem, as did PMB_2. Replicate OctC4_2 also exhibited susceptibility to tetracycline and tigecycline whilst this profile for OctC4_4 varied extensively for these antibiotics, where resistant and susceptible MICs were recorded depending on the colonies selected.

Octapeptin resistance induced isolates harbor an increase in hydroxymyristate and palmitoylate dissimilar to Ara4N lipid A modifications in Pmx-R strains.

In the initial isolate, MS/MS analysis of extracted lipid A fractions showed that the major singly charged peak was m/z 1824.2, which corresponded to a hexa-acylated lipid A species comprised of two phosphate groups, two glucosamines and four 3-hydroxy-myristoyl groups (3-OH-C₁₄), with two of these further acylated with myristate (C₁₄) (Fig. 3A, also see Fig. S1 in the supplemental material). Due to the low intensity of this peak and the maximum detection limit of 2000 Da, in the system used, doubly charged masses were examined (see Fig. S1A in the supplemental material). This mass correlated to a doubly charged species of m/z 911.6 herein designated as the wild-type (WT) lipid A. Lesser quantities of various modifications accompanied the WT lipid A in the initial strain, including a hydroxyl modification of a myristate (m/z 919.6, WT+C_{14:OH}), palmitoylation (m/z 1030.7 WT+C₁₆) and even the addition of Ara4N (m/z 977.1, WT+Ara4N), a modification known to confer polymyxin resistance (Fig. 3B). In sharp contrast, the predominant species found in Pmx-R isolates was the near complete loss of WT lipid A and fortification of Ara4N on phosphate groups, mainly in hydroxymyristate species (m/z 985.1, WT+C_{14:OH}+Ara4N; m/z 1042.7, WT+2(Ara4N); m/z 1050.7, WT+C_{14:OH}+2(Ara4N)) (Fig. 3B, see Fig. S2 and S3 in the supplemental material). These changes corresponded to the genetic changes described in the following sections. The other commonly reported lipid A modification for resistance, pEtN,

corresponding to m/z 973.2 was never observed. The lipid A from the OctC4 induced isolates was substantially different from the Pmx-R isolates and similar to the WT profile, with a major peak of the hydroxymyristate derivative and a significant 5-fold increase in representation of palmitoylation (Fig. 3B, see Fig. S4 in the supplemental material). The Ara4N modification was enhanced compared to WT, but not to the extent seen with Pmx-R isolates.

Plasmid loss associated with OctC4 resistance. To ascertain the genetic basis for resistance and subsequent phenotypic traits, four day 20 replicates were selected from each treatment group. Clonal expansion of genomic variations were monitored by selecting four colonies per replicate. Additionally, two colonies from the initial isolate were sequenced. The initial isolate harbored multiple acquired resistance genes targeting aminoglycosides, β -lactams, fosfomycin, quinolones, sulfonamides, tetracycline and trimethoprim, consistent with the parent XDR profile (Table 2). Five plasmid replicons were identified including ColRNAI, IncFIB(K)-Kpn3, IncFII(K), IncN and IncX3. In cross-resistance studies, the only Pmx-R replicate with an alteration in MIC profile to other antibiotics was PMB_2. Unique to PMB_2 was the susceptibility to meropenem and a reduction in resistance towards cefepime. Sequencing revealed a lack of *aph(3')-Ia*, *blaKPC-2*, *blaOXA-9* and no evidence of the IncX3 replicon in all four colonies. There was also a partial loss of this plasmid in PMB_4 (Table 2).

High variability of acquired resistance genes and plasmids were witnessed for OctC4 exposed replicates. Resistance genes impacted included *aph(3')-Ia*, *aph(3'')-Ib*, *aph(6)-Id*, *blaKPC-2*, *blaOXA-9*, *blaTEM-1B*, *sul2*, *tet(A)* and *dfrA14*. Furthermore, plasmid replicon loss was apparent in three of the four replicates including IncFIB(K)-Kpn3, IncFII(K) and IncN. Subtle discrepancies in β -lactamase genes were observed across the three treatment groups; however, this was attributed to difficulties in the assembly due to high homology amongst these genes.

Chromosomal variations in lipopolysaccharide pathways associated with polymyxin

resistance whilst phospholipid transport associated with OctC4 resistance. Genomic

alterations identified in polymyxin and OctC4 treated replicates differed significantly. In Pmx-R

replicates, genes predominantly associated with LPS processing and lipid A modifications were

altered, including *crrB*, *hepIII*, *lptC*, *mgrB*, *pmrB*, *phoPQ* and *yciM* (Table 3). An additional TCS

gene, *qseC*, was also disrupted in PMB_3 (S8R, I283L) and PMB_4 (L40F). Although similar

genes were impacted across replicates, the mutation positions differed. Additionally, an

accumulation of variations in LPS pathways were apparent within a single replicate. All four

colonies from a single replicate were commonly changed indicating clonal expansion of this

variant. Complementation assays were further conducted to unveil the contributions of these genes

to observed resistance (Fig. 4). Polymyxin susceptibility was restored in CST_2 (complete deletion

of *mgrB*), CST_3 (M1I), CST_4 (N42I), PMB_2 (W47L) and PMB_4 (D29Y) once complemented

with pTOPO-*mgrB* (Fig. 4B-D, F and H). The PmrB (P95L) variant in PMB_1 was validated to

contribute to resistance (Fig. 4E). Alterations in CrrB (D57V), PhoP (R81C) and QseC (S8R,

I283L) were confirmed to cause resistance once these genes were introduced into the initial strain

(Fig. 4M). Subtle increases in polymyxin MIC was detected for PhoQ (P420A, G434C), PhoQ

(D417N) and QseC (L40F) but did not surpass the breakpoint (Fig. 4M). This confirms the

presence of multiple resistance conferring mutations being present in a single isolate and several

contributing to the elevation of MIC.

The OctC4 replicates harbored changes in *mldF*, *pqiB* and *traH* in all four colonies. Additional

genes altered that were apparent in two colonies per replicate included *azoR*, *hinT* and *rpsA*.

Strikingly, *mldF* (A165P) was impacted in three different OctC4 replicates at the same position

(Table 3). Complementation assays that introduced pTOPO-*mldF*, -*mldF* or -*pqiB* into OctC4

191 induced replicates reduced the MIC by 2-fold, however, consistently only partial growth was
 192 observed at 8 µg/ml. This finding validates the partial contribution of these genes to resistance
 193 (Fig. 4I-L). Introduction of WT genes into the initial isolate revealed that the vector and gene did
 194 not influence the MIC and confirmed that these alterations are responsible for the resistance
 195 observed (Fig. 4M and N).

DISCUSSION

Polymyxin unfortunately now induce high levels of resistance during therapeutic use, which is further compromised by suboptimal exposure in the clinic due to the risk of nephrotoxicity (29). Resistance in *K. pneumoniae* appears to be stable and incurs a minimal fitness cost (30, 31). These clinical characteristics were reflected in our study whereby once the isolate could tolerate 0.5 µg/ml of either CST or PMB, the clinical breakpoint was vastly exceeded within 48 h, well within the duration of clinical antibiotic therapy. This rapid induction of resistance was not observed for OctC4, in which only comparatively minor increases in MIC were observed. The slow progression in resistance profile could be an advantageous characteristic of OctC4 as a potential clinical intervention.

Following 20 days of increasing sub-lethal antibiotic exposure, no cross-resistance was apparent between polymyxins and OctC4. CST and PMB resulted in similar profiles with the only deviation seen in sample PMB_2 in which susceptibility to meropenem was regained. This is due to the absence of *blaKPC-2* and *blaOXA-9*. Additionally, the homogenous loss of the IncX3 plasmid was identified. Clinically, meropenem is being used in combination with polymyxins, and these results suggest that, in some cases, meropenem may overcome polymyxin resistance (32, 33). Furthermore, previous research has identified the loss of *blaKPC* plasmids in Pmx-R clinical isolates and suggests that this loss is due to a potential fitness cost (34). Our results show various accounts of plasmid loss in OctC4-exposed replicates, and this corresponded to a reduction in resistance towards cefepime, meropenem and tetracycline. Whether this resembles a fitness cost associated with OctC4 exposure or due to repeated passaging under no selective pressure for the genes harbored on these plasmids warrants further investigation.

Interestingly, resistance towards chloramphenicol was diminished in polymyxin and OctC4 exposed strains. Resistance towards chloramphenicol can arise from plasmid-encoded chloramphenicol acetyltransferases, alterations in the target 50S ribosomal subunit, or disruptions in porins and efflux pumps (35). The absence of acquired resistance genes and the lack of modifications in these regions may imply either a down-regulation of efflux pumps or an alternative resistance mechanism. The synergistic mechanism of polymyxins and chloramphenicol have been extensively studied; however, this finding potentially indicates a novel loss of chloramphenicol resistance upon gaining resistance towards these lipopeptides (36, 37), and is also seen with the octapeptins.

The mutations observed in polymyxin resistance induced ST258 strains can be compared to those we have previously identified in closely related polymyxin-resistant clinical ST258 isolates, 2_GR_12, 4_GR_12, 10_GR_13, 13_GR_14 and 14_GR_14 (24). As in this study, the vast majority of resistance was attributed to *mgrB* (60%), albeit not via an IS element disruption commonly observed in the clinic. Additional mutations were also identified in *phoPQ* accompanying the *mgrB* disruption, which was also apparent in this study (CST_3, CST_4, PMB_2). Other mutations in *crrB*, *mgrB*, *pmrB*, *phoPQ* and *yciM* in acquisition of polymyxin resistance have previously been described in resistant strains (16, 17, 38). Taken together, this indicates that resistance induction experiments have the capacity to induce genomic changes observed in the clinic.

These mutations lead to increased levels of Ara4N-modified lipid A, as observed in the lipid A analysis. Interestingly, the initial polymyxin-susceptible isolate exhibited Ara4N lipid A modifications which reveals a heteroresistant strain where a subpopulation of resistant bacteria exists within a phenotypically susceptible isolate. In several instances for polymyxin induced

isolates, mutations were present in multiple genes within a replicate. CST_3 harbored a deleterious mutation in *mgrB* (M1I) and additional alterations in *phoQ* (P420A, G434C) increased tolerance to CST. This was also the circumstance for CST_4 (*mgrB*: N42I, *phoQ*: D417N). PMB_2 possessed a resistance conferring mutation in *mgrB* (W47L) and *phoP* (R81C). The notion that one alteration in TCS drives resistance, the circumstance for the majority of clinical isolates is well accepted (39). However, our findings contradict this concept.

We also identified alterations in another TCS, QseBC, which is known to facilitate cross-talk with PmrAB in *Escherichia coli* (40). In *E. coli*, PmrB acts as a noncognate partner to the QseBC TCS and has the capability to not only phosphorylate PmrA, but also QseB. The absence of QseC was shown to impact virulence due to the accumulation of phosphorylated QseB and in particular, alterations in the histidine kinase domain attenuates its ability to de-phosphorylate QseB (40, 41). Furthermore, the deletion of *qseC* and *pmrA*, promoting phosphorylation of QseB by PmrB, stimulated tolerance to PMB (42). This signalling pathway remains severely under characterized in *K. pneumoniae*. We observed partial tolerance to PMB when a frameshift mutation was apparent at nucleotide 118; however, full resistance in PMB_4 was promoted by alterations in *mgrB* (D29Y) and *yciM* (V43G), which has recently been identified to cause resistance (38). Conversely, PMB_3 also harbored a frameshift mutation early in the coding sequence of *qseC* (GCCTGAGCCTGC17 Δ^{fs}), although an additional I283L change in the histidine kinase region resulted in an MIC of 4 $\mu\text{g/ml}$. This did not explain the full resistance profile exhibited by PMB_3 and due to the presence of both alleles during complementation, the true extent of resistance cannot be deduced. Considering PMB_3 still resulted in the addition of Ara4N to lipid A, we speculate that due to the perturbation in the QseC kinase, this is increasing the accumulation of phosphorylated QseB and allows for the up-regulation of transcriptional targets. Subsequent

transcription could be activating PmrA, similar to other TCS in *K. pneumoniae*, allowing for the expression of the *pmrHFIJKLM* operon (Fig. 5A).

The mutation pattern was greatly different in OctC4-exposed replicates, with all harboring alterations in the Mla pathway. These genes are responsible for phospholipid (PL) importation from the outer membrane into the cell (43). Removal of *miaC* in *E. coli* was previously identified to increase the abundance of palmitoylated lipid A to stabilise the outer membrane which correlated to the phenotype in our study. Similarly, prior research exposing *P. aeruginosa* to OctC4 (32 µg/ml) revealed an increase in palmitoylated lipid A (22). Literature reports have demonstrated that octapeptins have the capacity to bind to PLs (44), and likely OctC4 utilises this pathway in order to traverse to the outer membrane (Fig. 5B). The involvement of PqiB in membrane integrity has only recently been characterized in *E. coli* (45). PqiB was identified to connect to PqiC and potentially deliver substrate/s from the outer to inner membrane. The contribution of the PqiABC appeared minimal compared to the Mla pathway and was proposed to either ineffectively transport PLs or transport different substrates with a minute impact on membrane integrity. The contribution of the Pqi and Mla pathway appeared to be additive when evaluating the MIC reduction in OctC4_1 and OctC4_2. Further genes impacted not homogeneous amongst the colonies included *rpsA* (40S ribosomal protein), *azoR* (quinone reductase), *traH* (plasmid conjugal transfer protein) and *hinT* (purine nucleoside phosphoramidase), which may indicate several intracellular targets (46-49). The lack of mutations associated with Ara4N-modifications to lipid A is consistent with the lipid A profile of the OctC4-induced isolates. This observation supports the hypothesis that the octapeptins work by a different mode of action compared to the polymyxins, one that does not require an initial binding to lipid A and explains the lack of cross-resistance between the two classes of lipopeptides. However, further studies are required to determine if this occurs

287 ubiquitously for *K. pneumoniae* and if the same phenomenon is observed for other Gram-negative
 288 pathogens. The slow progression of resistance, potential fitness cost if resistance develops, and the
 289 alternative mechanism of infiltration of OctC4 highlight the potential for octapeptins to be
 290 explored as future antibiotics.

MATERIALS AND METHODS

Bacterial strains and growth conditions. Clinical polymyxin-susceptible XDR *K. pneumoniae* ST258 isolate, 20_GR_12, was sourced through Hygeia General Hospital, Athens, Greece as previously described (24). Cultures were grown in Luria-Bertani (LB) broth and for single colony isolation, cultures were grown on either LB or Nutrient Agar (NA) plates.

Antimicrobial susceptibility assays. Minimum inhibitory concentration was determined by the broth microdilution method according to Clinical & Laboratory Standards Institute (CLSI) guidelines (50). Cultures were grown in cation-adjusted MHB and to assess cross-resistance of day 20 isolates, broth was supplemented with the concentration of antibiotic tolerated at that time point (see Table S1 in the supplemental material). Clinical breakpoints were determined in concordance to CLSI guidelines (51) and tigecycline as per The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (Version 8.0, 2018) (see <http://www.eucast.org>).

Induction of resistance. A single colony of the clinical isolate was selected and grown overnight at 37°C shaking at 220 rpm. Similar to the broth microdilution assay, this culture was grown to log phase ($OD_{600} = 0.4-0.6$). The culture was plated out into three separate 96-well polystyrene, non-treated plates (Sigma Aldrich) with six replicates for each treatment group including CST, PMB and OctC4. Plates were incubated overnight and OD_{600} was read at 20 h. The well which harbored dense growth ($OD_{600} \geq 1$) underwent a 1:1000 dilution, transferred to a new plate with the concentration range adjusted accordingly. The highest concentration used for the polymyxins was 128 $\mu\text{g/ml}$ and 32 $\mu\text{g/ml}$ for OctC4. This process was completed for 20 days with five following days of no antibiotic exposure. At day 20, the culture was further diluted (1:1000) and placed in non-supplemented broth to be incubated overnight. Part of this culture underwent an MIC against the antibiotic it was exposed to in order to evaluate stability of resistance. Several

time points were isolated and stored in 30% sterile glycerol at -80°C for future assays. Fold change significance was determined via GraphPad Prism 7 with a one-way ANOVA with a Tukey's multiple comparisons test where significance was $P < 0.05$.

Lipid A modifications. Lipid A was extracted using the ammonium hydroxide-isobutyric acid protocol as previously described (52). Day 20 cultures were grown overnight in LB supplemented with antibiotic (see Table S1 in the supplemental material). Overnight inoculums were subcultured (1:100) into 100 mL LB broth and grown to an $OD_{600} = 0.8-1$. Cultures were pelleted (10,000 rpm, 20 min, 4°C), washed with 1X PBS (10,000 rpm, 15 min, 4°C) and freeze dried. 10 mg of lyophilised cells were processed as per (52). Concisely, samples were suspended in isobutyric acid:ammonium hydroxide (5:3 [vol/vol]), under magnetic stirring at 100°C for 4 h, supernatants isolated by centrifugation at 13,000 rpm for 15 min, diluted with equal volume of water and freeze dried. Extracts then underwent two methanol washes (4,000 rpm, 15 min). The extracted lipid A was solubilised in methanol containing 5 mM ammonium acetate to a concentration of 1 µg/ml. Samples were infused at a low rate of 5 µl/min into a QSTAR Elite (Applied Biosystems) hybrid quadrupole Time-of-Flight (TOF) mass spectrometer. To acquire adequate fragmentation for MS/MS analysis, the collision energy was increased from 40 to 80. Averaged spectra were accumulated over at least 1 min. Data were exported from Analyst (SCIEX), normalized to the highest mass intensity and graphed in GraphPad Prism 7.

DNA extractions and library preparation. Glycerol stocks from day 20 isolates were grown on NA plates overnight. Single colonies were isolated, grown in antibiotic supplemented broth (see Table S1 in the supplemental material), incubated overnight and DNA extracted using the DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer's guidelines. Two colonies were selected from day 0 and 4 colonies from 4 replicates per treatment group. Quantification of DNA

was acquired using Qubit®3.0 (ThermoFisher Scientific) and 1 ng of DNA underwent library preparation with the Nextera XT kit (Illumina) as per manufacturer's instructions. Quality control was checked with a 2100 Bioanalyzer (Agilent Technologies) and LabChip GX (PerkinElmer).

Sequencing and analysis. Libraries were sequenced on an Illumina NextSeq with 150 bp paired end sequencing reads with $\geq 95X$ coverage with the exception of CST_2 (colony 1) (48X). Trimmomatic (53) was used to trim paired end reads and SPAdes v3.10.1 implemented for assembly (54). Annotation of assembled genomes was accomplished using the Rapid Annotation using Subsystem Technology (RAST) (55). The Centre for Genomic Epidemiology (CGE) tools were implemented to delineate laterally acquired resistant genes (ResFinder 3.0) (56) and plasmids (PlasmidFinder 1.3) (57). Reads were aligned using BWA-MEM (58), analyzed through FreeBayes (59) and impact of change determined through snpEff (60). Nucleotide sequences have been deposited under NCBI BioProject PRJNA415530 (www.ncbi.nlm.nih.gov/bioproject/415530).

Complementation assays. Genes speculated to cause resistance underwent complementation as previously described (61). Briefly, genes harboring a potential variation contributing to resistance was amplified using the 2X Phusion HF master mix (ThermoFisher) with primers listed in Table S2 in the supplemental material. The gene was cloned into the pCR-BluntII-TOPO using the Zero Blunt TOPO PCR cloning kit (Invitrogen). The plasmid was transformed in electrocompetent *E. coli* TOP10 via electroporation, grown overnight on MHB agar supplemented with kanamycin (50 µg/ml) at 37°C overnight and plasmids extracted using the QIAprep spin miniprep column kit (Qiagen). Plasmids were transformed into the initial susceptible strain (20_GR_12) and incubated overnight on MHB agar containing zeocin (1500 µg/ml). Furthermore, the wild-type gene was

amplified from the initial strain and placed into the resistant day 20 isolates. An MIC was conducted to determine if resistance was altered as mentioned above.

ACKNOWLEDGEMENTS

MAC is an NHMRC Principal Research Fellow (APP1059354) and currently holds a fractional Professorial Research Fellow appointment at the University of Queensland with his remaining time as CEO of Inflazome Ltd. a company headquartered in Dublin, Ireland that is developing drugs to address clinical unmet needs in inflammatory disease by targeting the inflammasome. LJMC is an ARC Future Fellow (FT110100972). MEP is an Australian Postgraduate Award scholar. MATB is supported in part by a Wellcome Trust Strategic Award 104797/Z/14/Z. Research was supported by NHMRC grants APP1005350, APP1045326 and NIH grant R21AI098731/R33AI098731-03. We would like to acknowledge Dr Ilias Karaikos and Dr Helen Giamarellou for supplying this clinical isolate and Dr Alysha Elliott for the initial characterization of the strain. We thank Dr Alejandra Gallardo-Godoy, Dr Karl Hansford, David Edwards and Ruby Pelingon for the synthesis and purification of OctC4, Dr Tim Bruxner and Angelika Christ for their support with the sequencing, Alun Jones with his assistance for mass spectrometry which was acquired at the IMB Mass Spectrometry Facility at UQ, and Dr Hannah Sidjabat for her assistance with the initial quality control of the resistance induced strains.

Author contributions. MEP, MAC, LJMC, MATB conceived this study. MEP, MDC and DG performed the sequencing analysis and MEP, MSB and SR performed the experiments. MEP wrote the paper with the input from other authors.

Conflict of interest. None.

REFERENCES

1. Bhatt P, Tandel K, Shete V, Rathi KR. 2015. Burden of extensively drug-resistant and pandrug-resistant Gram-negative bacteria at a tertiary-care centre. *New Microbes New Infect* 8:166-170.
2. Karaiskos I, Giamarellou H. 2014. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. *Expert Opin Pharmacother* 15:1351-1370.
3. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. 2009. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. *J Antimicrob Agents* 35:240-243.
4. Arca P, Reguera G, Hardisson C. 1997. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. *J Antimicrob Chemother* 40:393-399.
5. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Lui JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161-168.
6. Tsuruoka T, Miyata A, Yamada Y. 1978. Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of *Escherichia coli* K-12. *J Antibiot (Tokyo)* 31:192-201.

- 403 7. Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. 2013. The emergence of clinical resistance
404 to tigecycline. *Int J Antimicrob Agents* 41:110-116.
- 405 8. Cheng HY, Chen YF, Peng HL. 2010. Molecular characterization of the PhoPQ-PmrD-
406 PmrAB mediated pathway regulating polymyxin B resistance in *Klebsiella pneumoniae*
407 CG43. *J Biomed Sci* 17:60.
- 408 9. Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, Tryfinopoulou K,
409 Vatopoulos A, Rossolini GM, COLGRIT Study Group. 2014. MgrB inactivation is a
410 common mechanism of colistin resistance in KPC-producing *Klebsiella pneumoniae* of
411 clinical origin. *Antimicrob Agents Chemother* 58:5696-5703.
- 412 10. Becker B, Butler MS, Hansford KA, Gallardo-Godoy A, Elliott AG, Huang JX, Edwards
413 DJ, Blaskovich MAT, Cooper MA. 2017. Synthesis of octapeptin C4 and biological
414 profiling against NDM-1 and polymyxin-resistant bacteria. *Bioorg Med Chem Lett*
415 27:2407-2409.
- 416 11. Velkov T, Roberts KD, Li J. 2017. Rediscovering the octapeptins. *Nat Prod Rep* 34:295-
417 309.
- 418 12. Qian CD, Wu XC, Teng Y, Zhao WP, Li O, Fang SG, Huang ZH, Gao HC. 2012. Battacin
419 (Octapeptin B5), a new cyclic lipopeptide antibiotic from *Paenibacillus tianmuensis* active
420 against multidrug-resistant Gram-negative bacteria. *Antimicrob Agents Chemother*
421 56:1458-1465.
- 422 13. Koike M, Iida K, Matsuo T. 1969. Electron microscopic studies on mode of action of
423 polymyxin. *J Bacteriol* 97:448-452.

14. Clausell A, Garcia-Subirats M, Pujol M, Busquets MA, Rabanal F, Cajal Y. 2007. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. *J Phys Chem B* 111:551-563.
15. Raetz CR, Reynolds CM, Trent MS, Bishop RE. 2007. Lipid A modification systems in gram-negative bacteria. *Annu Rev Biochem* 76:295-329.
16. Olaitan AO, Morand S, Rolain JM. 2014. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol* 5:643.
17. Cheng YH, Lin TL, Lin YT, Wang JT. 2016. Amino acid substitutions of CrrB responsible for resistance to colistin through CrrC in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 60:3709-3716.
18. Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Møller N, He H, Poudyal A, Li J, Nation RL, Vaara T. 2010. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. *Antimicrob Agents Chemother* 54:3341-3346.
19. Meyers E, Parker WL, Brown WE, Linnett P, Strominger JL. 1974. EM49: a new polypeptide antibiotic active against cell membranes. *Ann N Y Acad Sci* 235:493-501.
20. Chitty JL, Butler MS, Suboh A, Edwards DJ, Cooper MA, Fraser JA, Robertson AAB. 2017. Antimicrobial octapeptin C4 analogues active against *Cryptococcus* species. *Antimicrob Agents Chemother* pii: AAC.00986-17.
21. Han M-L, Shen HH, Hansford KA, Schneider EK, Sivanesan S, Roberts KD, Thompson PE, Le Brun AP, Zhu Y, Sani MA, Separovic F, Blaskovich MAT, Baker MA, Moskowitz SM, Cooper MA, Li J, Velkov T. 2017. Investigating the interaction of Octapeptin A3 with model bacterial membranes. *ACS Infect Dis* 3:606-619.

22. Velkov T, Gallardo-Godoy A, Swarbrick JD, Blaskovich MAT, Elliott AG, Han M, Thompson PE, Roberts KD, Huang JX, Becker B, Butler MS, Lash LH, Henriques ST, Nation RL, Sivanesan S, Sani M-A, Separovic F, Mertens H, Bulach D, Seemann T, Owen J, Li J, Cooper MA. Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria. *Cell Chem Biol* doi:10.1016/j.chembiol.2018.01.005.
23. Meyers E, Pansy FE, Basch HI, McRipley RJ, Slusarchyk DS, Graham SF, Trejo WH. 1973. EM49, a new peptide antibiotic. III. biological characterization *in vitro* and *in vivo*. *J Antibiot (Tokyo)* 26:457-462.
24. Pitt ME, Elliott AG, Cao MD, Ganesamoorthy D, Karaikos I, Giamarellou H, Abboud CS, Blaskovich MAT, Cooper MA, Coin LJM. 2018. Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant *Klebsiella pneumoniae*. *Microb Genom* doi: 10.1099/mgen.0.000158.
25. Navon-Venezia S, Kondratyeva K, Carattoli A. 2017. *Klebsiella pneumoniae*: a major worldwide source and shuttle for antibiotic resistance. *FEMS Microbial Rev* 41:252-275.
26. Bowers JR, Kitchel B, Driebe EM, MacCannell DR, Roe C, Lemmer D, de Man T, Rasheed JK, Engelthaler DM, Keim P, Limbago BM. 2015. Genomic analysis of the emergence and rapid global dissemination of the clonal group 258 *Klebsiella pneumoniae* pandemic. *PLoS One* 10: e0133727.
27. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. 2009. Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob Agents Chemother* 53:3365-3370.

28. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis* 13:785-796.
29. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kayes KS. 2011. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. *Clin Infect Dis* 53:879-884.
30. Arena F, Henrici De Angelis L, Cannatelli A, Di Pilato V, Amorese M, D'Andrea MM, Giani T, Rossolini GM. 2016. Colistin resistance caused by inactivation of the MgrB regulator is not associated with decreased virulence of sequence type 258 KPC carbapenemase-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 60:2509-2512.
31. Lee JY, Choi MJ, Choi HJ, Ko KS. 2015. Preservation of acquired colistin resistance in Gram-negative bacteria. *Antimicrob Agents Chemother* 60:609-612.
32. Lee GC, Burgess DS. 2012. Treatment of *Klebsiella pneumoniae* carbapenemase (KPC) infections: a review of published case series and case reports. *Ann Clin Microbiol Antimicrob* 11:32.
33. Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar T, Altunin S, Paul M, AIDA consortium. 2016. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the

- treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open 6:e009956.
34. Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, Kaye K, Jacobs MR, Bonomo RA, Adams MD. 2015. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of *Klebsiella pneumoniae* reveal multiple pathways of resistance. Antimicrob Agents Chemother 59:536-543.
35. Schwarz S, Kehrenberg C, Doublet B, Cloeckaert A. 2004. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiology Rev 28:519-542.
36. Civljak R, Giannella M, Di Bella S, Petrosillo N. 2014. Could chloramphenicol be used against ESKAPE pathogens? A review of *in vitro* data in the literature from the 21st century. Expert Rev Anti Infect Ther 12:249-264.
37. Abdul Rahim N, Cheah Se, Johnson MD, Yu H, Sidjabat HE, Boyce J, Butler MS, Cooper MA, Fu J, Paterson DL, Nation RL, Bergen PJ, Velkov, Li J. 2015. Synergistic killing of NDM-producing MDR *Klebsiella pneumoniae* by two 'old' antibiotics-polymyxin B and chloramphenicol. J Antimicrob Chemother 70:2589-2597.
38. Halaby T, Kucukkose E, Janssen AB, Rogers MR, Doorduijn DJ, van der Zanden AG, Al Naiemi N, Vandenbroucke-Grauls CM, van Schaik W. 2016. Genomic characterization of colistin heteroresistance in *Klebsiella pneumoniae* during a nosocomial outbreak. Antimicrob Agents Chemother 60:6837-6843.
39. Baron S, Hadjadj L, Rolain J-M, Olaitan AO. 2016. Molecular mechanisms of polymyxin resistance: knowns and unknowns. In J Antimicrob Agents 48:583-591.
40. Guckes KR, Kostakioti M, Breland EJ, Gu AP, Shaffer CL, Martinez CR 3rd, Hultgren SJ, Hadjifrangiskou M. 2013. Strong cross-system interactions drive the activation of the QseB

- response regulator in the absence of its cognate sensor. Proc Natl Acad Sci USA 110:16592-16597.
41. Breland EJ, Zhang EW, Bermudez T, Martinez CR III, Hadjifrangiskou M. 2017. The histidine residue of QseC is required for canonical signaling between QseB and PmrB in uropathogenic *Escherichia coli*. J Bacteriol 199:pii:e00060-17.
42. Guckes KR, Breland EJ, Zhang EW, Hanks SC, Gill NK, Algood HM, Schmitz JE, Stratton CW, Hadjifrangiskou M. 2017. Signaling by two-component system noncognate partners promotes intrinsic tolerance to polymyxin B in uropathogenic *Escherichia coli*. Sci Signal 10: pii: eaag1775.
43. Malinverni JC, Silhavy TJ. 2009. An ABC transport system that maintains lipid asymmetry in the Gram-negative outer membrane. Proc Natl Acad Sci USA 106:8009-8014.
44. Swanson PE, Paddy MR, Dahlquist FW, Storm DR. 1980. Characterization of octapeptin-membrane interactions using spin-labeled octapeptin. Biochemistry 19:3307-3314.
45. Nakayama T, Zhang-Akiyama Q-M. 2016. pqiABC and yebST, putative mce operons of *Escherichia coli*, encode transport pathways and contribute to membrane integrity. J Bacteriol 199: pii: e00606-16.
46. Duval M, Korepanov A, Fuchsbaauer O, Fechter P, Haller A, Fabbretti A, Choulier L, Micura R, Klaholz BP, Romby P, Springer M, Marzi S. 2013. *Escherichia coli* ribosomal protein S1 unfolds structured mRNAs onto the ribosome for active translation initiation. PLoS Biol 11:e1001731.
47. Liu G, Zhou J, Fu QS, Wang J. 2009. The *Escherichia coli* azoreductase AzoR Is involved in resistance to thiol-specific stress caused by electrophilic quinones. J Bacteriol 191:6394-6400.

48. Arutyunov D, Arenson B, Manchak J, Frost LS. 2010. F plasmid TraF and TraH are components of an outer membrane complex involved in conjugation. *J Bacteriol* 192:1730-1734.
49. Chou TF, Bieganowski P, Shilinski K, Cheng J, Brenner C, Wagner CR. 2005. ³¹P NMR and genetic analysis establish *hinT* as the only *Escherchia coli* purine nucleoside phosphoramidase and as essential for growth under high salt conditions. *J Biol Chem* 280:15356-15361.
50. Clinical and Laboratory Standards Institute. 2015. M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Tenth Edition. CLSI, Wayne, PA.
51. Clinical and Laboratory Standards Institute. 2016. Performance Standards for Antimicrobial Susceptibility Testing— Twenty-sixth Edition: Approved standard M100S. CLSI, Wayne, PA.
52. Choi MJ, Ko KS. 2015. Loss of hypermucoviscosity and increased fitness cost in colistin-resistant *Klebsiella pneumoniae* sequence type 23 strains. *Antimicrob Agents Chemother* 59:6763-6773.
53. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114-2120.
54. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 19:455-477.

55. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST Server: rapid annotations using subsystems technology. *BMC Genomics* 9:75.
56. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 67:2640-2644.
57. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895-3903.
58. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25:1754-1760.
59. Garrison E, Marth G. 2012. Haplotype-based variant detection from short-read sequencing. *arXiv preprint arXiv:1207.3907 [q-bio.GN]*.
60. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. 2012. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* 6:80-92.
61. Jayol A, Poirel L, Brink A, Villegas MV, Yilmaz M, Nordmann P. 2014. Resistance to colistin associated with a single amino acid change in protein PmrB among *Klebsiella pneumoniae* isolates of worldwide origin. *Antimicrob Agents Chemother* 58:4762-4766.

FIGURES & TABLES

FIG 1 Structural comparison between the 3 lipopeptide antibiotics used in this study. Colistin (A) and polymyxin B (B) differ by one amino acid (polymyxin B: **phenylalanine** and colistin: **leucine** (**R¹**)). One defining feature of octapeptin C4 (C) is that it contains 8 amino acids rather than 10 in polymyxins. In addition, a **leucine** residue replaces **threonine** within the ring (**R²**), the exocyclic **diaminobutyric acid (Dab)** residue is the D-enantiomer, and the **fatty acid tail** contains a 3-hydroxy group (**R³**).

599

610

611 **FIG 2** Acquired resistance in extensively drug-resistant *K. pneumoniae* over time for polymyxins
612 and octapeptin C4. (A) Colistin (B) Polymyxin B (C) Octapeptin C4 (D) Overall comparison of
613 acquired resistance for 20 day antibiotic exposure and 5 days following without exposure
614 (mean±SEM, n=6) (E) Fold change of colistin (CST), polymyxin B (PMB), and octapeptin C4
615 (OctC4) in concordance to day 0 and 20 MIC (mean±SD) (*****P*<0.001). Line represents break
616 points (2 μg/ml polymyxins, 8 μg/ml set for octapeptin to highlight divergence from day 0).
617 Highest concentration used for polymyxins was 128 μg/ml and 32 μg/ml for octapeptin C4.

A

B

$[M-2H]^{2-}$	Species	Initial	CST	PMB	OctC4
911.6	WT	100.0±0.0	6.2±4.6	9.6±4.8	84.2±7.6
919.6	WT+OH	39.5±1.1	10.8±7.6	27.0±13.7	100±0.0
977.1	WT+Ara4N	50.5±0.1	57.4±32.1	46.6±19	34.0±5.4
985.1	WT+OH+Ara4N	22.7±0.2	78.9±38.7	88.6±18.9	45.1±3.5
1030.7	WT+C ₁₆	21.5±3.0	4.1±3.3	16.0±14.0	41.9±6.4
1038.7	WT+OH+C ₁₆	9.9±0.0	3.7±3.4	29.0±14.0	62.8±4.4
1042.7	WT+2(Ara4N)	2.5±0.2	56.0±28.2	18.3±8.5	2.9±1.1
1050.7	WT+OH+2(Ara4N)	1.2±0.1	64.6±36.4	30.7±16.3	2.3±0.3
1096.3	WT+Ara4N+C ₁₆	9.5±0.9	33.6±20.3	48.4±32.2	8.6±1.5
1104.3	WT+OH+Ara4N+C ₁₆	5.2±0.5	33.3±18.5	70.5±28.1	21.6±3.2
1161.8	WT+2(Ara4N)+C ₁₆	0.4±0.0	31.2±14.2	11.7±8.5	0.5±0.1
1169.8	WT+OH+2(Ara4N)+C ₁₆	0.3±0.0	26.3±20.4	12±5.7	0.5±0.1

FIG 3 Lipid A modifications identified after 20 days of exposure to either colistin, polymyxin B or octapeptin C4. (A) Modifications which were detected in wild-type (WT) hexa-acylated lipid A. This included hydroxylation of a myristate (R^1), palmitoylation (R^2) and the addition of 4-amino-4-deoxy-arabinose (Ara4N) to either phosphate groups (R^3 , R^4). (B) Doubly charged lipid A species detected for the initial isolate (n=2) and treatment groups (n=6). Values represent mean±SD of relative peak intensities.

631

632

633

645

646

647

648

FIG 4 Complementation assays to delineate contribution of variations detected in day 20 treated strains to resistance. (A-D) Colistin treatment groups complemented with WT gene. (A) CST_1 with pTOPO-*corrB*. (B) CST_2 with pTOPO-*mgrB*. (C) CST_3 with pTOPO-*mgrB* or pTOPO-*phoQ*. (D) CST_4 with pTOPO-*mgrB* or pTOPO-*phoQ*. (E-H) Polymyxin B treatment groups complemented with WT gene. (E) PMB_1 with pTOPO-*pmrB*. (F) PMB_2 with pTOPO-*mgrB* or pTOPO-*phoP*. (G) PMB_3 with pTOPO-*qseC*. (H) PMB_4 with pTOPO-*mgrB* or pTOPO-*qseC*. (I-L) Octapeptin C4 treatment groups complemented with WT gene. (I) OctC4_1 with pTOPO-*mldD* or pTOPO-*pqiB* (J) OctC4_2 with pTOPO-*mldF* or pTOPO-*pqiB*. (K) OctC4_3 and with pTOPO-*mldF*. (L) OctC4_4 with pTOPO-*mldF*. (M) 20_GR_12, the initial strain, complemented with WT genes and genes harboring mutations potentially causing polymyxin resistance. (N) Complementation of octapeptin C4 resistance associated WT genes in 20_GR_12. The (-) indicates no complementation was conducted and represents the initial MIC. The y-axis split signifies the breakpoint for polymyxins (2 µg/ml) and initial MIC for octapeptin C4 (8 µg/ml). Values represented as mean±SD (n=4). Values above bars (A-L) indicate amino acid change in induced resistant isolate. Δ represents a complete deletion of protein and * is a stop codon.

670

671 **FIG 5** Proposed pathway associated with *K. pneumoniae* polymyxin and octapeptin C4 resistance

672 observed in this study. (A) To facilitate resistance against polymyxins, genomic variations are

673 acquired in two-component regulatory systems. These encompass CrrAB, QseBC, PmrAB and

674 PhoPQ with MgrB acting as a negative repressor. Once this pathway is activated during resistance,

675 sensor histidine kinases (CrrB, QseC, PmrB, PhoQ) will phosphorylate response regulators (CrrA,

676 QseB, PmrA, PhoP) and allow for the expression of target genes (*crrC*, unknown (?), *pmrD*,

677 *pmrHFIJKLM*). Disruptions in MgrB allow for the up-regulation of this pathway resulting in the

678 expression of *pmrHFIJKLM* which allows for 4-amino-4-deoxy-arabinose or

679 phosphoethanolamine to be attached to phosphate groups on lipid A. (B) The major disruptions

680 identified during octapeptin C4 resistance was in the Mla and Pqi pathway. OmpC removes

681 phospholipids (PLs) from the outer member and transfers these to MlaA. PLs are transported
 682 across the periplasm via MlaC and transported to the MlaBDEF complex where the subsequent
 683 fate of PLs is unknown. An unknown porin complexes with PqiC to transport metabolites and
 684 potentially PLs across the periplasm via the PqiAB complex. Perturbations in these pathways
 685 elevated the MIC towards octapeptin C4 and subsequent hydroxymyristate and palmitoylation of
 686 lipid A to potentially stabilise the outer membrane.

TABLE 1 Minimum inhibitory concentrations of day 20 replicates compared to initial isolate across several antibiotic classes

Strain ^a	Minimum inhibitory concentration (µg/ml) ^b														
	CST	PMB	OctC4	AMX	ATM	FEP	CRO	CHL	CIP	GEN	MEM	PIP	TET	TGC	TMP
Initial	≤0.25 ^S	≤0.125 ^S	8.00	>64.0 ^R	>64.0 ^R	≥16.0 ^R	>64.0 ^R	≥32.0 ^R	>64.0 ^R	≤4.00 ^S	≥32.0 ^R	>64.0 ^I	>64.0 ^R	≤2.00 ^{S,I}	>64.0 ^R
CST_1	>128 ^R	>128 ^R	≤8.00	>64.0 ^R	>64.0 ^R	≥16.0 ^R	>64.0 ^R	≤8.00 ^S	≥32.0 ^R	4.00 ^S	≥32.0 ^R	>64.0 ^I	>64.0 ^R	≤4.00 ^{S,R}	>64.0 ^R
CST_2	>128 ^R	>128 ^R	≤4.00	>64.0 ^R	>64.0 ^R	>64.0 ^R	>64.0 ^R	4.00 ^S	≥32.0 ^R	≤4.00 ^S	≥32.0 ^R	>64.0 ^I	>64.0 ^R	2.00 ^I	>64.0 ^R
CST_3	≥128 ^R	≥128 ^R	≤4.00	>64.0 ^R	>64.0 ^R	>64.0 ^R	>64.0 ^R	8.00 ^S	>64.0 ^R	≤4.00 ^S	>64.0 ^R	>64.0 ^I	>64.0 ^R	≤4.00 ^{I,R}	>64.0 ^R
CST_4	>128 ^R	>128 ^R	≤8.00	>64.0 ^R	>64.0 ^R	>64.0 ^R	>64.0 ^R	≤8.00 ^S	>64.0 ^R	≤4.00 ^S	>64.0 ^R	>64.0 ^I	>64.0 ^R	≤4.00 ^{I,R}	>64.0 ^R
CST_5	>128 ^R	>128 ^R	2.00	>64.0 ^R	>64.0 ^R	>64.0 ^R	>64.0 ^R	≤8.00 ^S	>64.0 ^R	≤4.00 ^S	>64.0 ^R	>64.0 ^I	>64.0 ^R	≤4.00 ^{I,R}	>64.0 ^R
CST_6	>128 ^R	>128 ^R	≤8.00	>64.0 ^R	>64.0 ^R	>64.0 ^R	>64.0 ^R	8.00 ^S	>64.0 ^R	≤4.00 ^S	>64.0 ^R	>64.0 ^I	>64.0 ^R	≥4.00 ^R	>64.0 ^R
PMB_1	128 ^R	128 ^R	≤4.00	>64.0 ^R	>64.0 ^R	>64.0 ^R	32.0 ^R	4.00 ^S	32.0 ^R	≤4.00 ^S	>64.0 ^R	>64.0 ^I	>64.0 ^R	≤4.00 ^{I,R}	>64.0 ^R
PMB_2	>128 ^R	>128 ^R	8.00	>64.0 ^R	>64.0 ^R	≤8.00 ^I	>64.0 ^R	4.00 ^S	>64.0 ^R	≤4.00 ^S	≤0.25 ^S	>64.0 ^I	>64.0 ^R	≤2.00 ^{S,I}	>64.0 ^R
PMB_3	>128 ^R	>128 ^R	4.00	>64.0 ^R	>64.0 ^R	≥32.0 ^R	>64.0 ^R	8.00 ^S	>64.0 ^R	2.00 ^S	≥32.0 ^R	>64.0 ^I	>64.0 ^R	2.00 ^I	>64.0 ^R
PMB_4	>128 ^R	>128 ^R	4.00	>64.0 ^R	>64.0 ^R	≥8.00 ^{I,R}	≥32.0 ^R	≤2.00 ^S	48.00 ^R	2.00 ^S	≥8.00 ^R	>64.0 ^I	>64.0 ^R	2.00 ^I	>64.0 ^R
PMB_5	>128 ^R	>128 ^R	≤8.00	>64.0 ^R	>64.0 ^R	≥8.00 ^{I,R}	≥32.0 ^R	≤8.00 ^S	>64.0 ^R	≤4.00 ^S	≥2.00 ^{I,R}	>64.0 ^I	>64.0 ^R	≤2.00 ^{S,I}	>64.0 ^R
PMB_6	>128 ^R	>128 ^R	≤8.00	>64.0 ^R	>64.0 ^R	≥16.0 ^R	>64.0 ^R	8.00 ^S	>64.0 ^R	≤4.00 ^S	≥32.0 ^R	>64.0 ^I	>64.0 ^R	≤4.00 ^{I,R}	>64.0 ^R
OctC4_1	0.25 ^S	≤0.25 ^S	32.0	>64.0 ^R	>64.0 ^R	≥16.0 ^R	>64.0 ^R	8.00 ^S	>64.0 ^R	≤2.00 ^S	≥32.0 ^R	>64.0 ^I	>64.0 ^R	≤2.00 ^{S,I}	>64.0 ^R
OctC4_2	0.25 ^S	0.25 ^S	32.0	>64.0 ^R	>64.0 ^R	≥8.00 ^{I,R}	>64.0 ^R	8.00 ^S	>64.0 ^R	≤2.00 ^S	≥32.0 ^R	>64.0 ^I	≤2.00 ^S	≤1.00 ^S	≥8.00 ^R
OctC4_3	≤0.5 ^S	0.25 ^S	32.0	>64.0 ^R	>64.0 ^R	≤4.00 ^{S,I}	32.0 ^R	8.00 ^S	>64.0 ^R	≤4.00 ^S	≤0.25 ^S	>64.0 ^I	>64.0 ^R	2.00 ^I	>64.0 ^R
OctC4_4	≤0.5 ^S	0.25 ^S	>32.0	>64.0 ^R	>64.0 ^R	≤4.00 ^{S,I}	32.0 ^R	8.00 ^S	>64.0 ^R	1.00 ^S	≤0.25 ^S	>64.0 ^I	≥2.00 ^{S,R}	≤2.00 ^{S,I}	≥4.00 ^R
OctC4_5	0.50 ^S	0.50 ^S	32.0	>64.0 ^R	>64.0 ^R	>64.0 ^R	>64.0 ^R	≤8.00 ^S	>64.0 ^R	2.00 ^S	>64.0 ^R	>64.0 ^I	>64.0 ^R	2.00 ^I	>64.0 ^R
OctC4_6	≤0.5 ^S	≤0.5 ^S	32.0	>64.0 ^R	>64.0 ^R	≤4.00 ^{S,I}	≥32.0 ^R	≤16.0 ^{S,I}	>64.0 ^R	2.00 ^S	≤0.25 ^S	>64.0 ^I	>64.0 ^R	2.00 ^I	>64.0 ^R

690 ^aInitial polymyxin-susceptible isolate is 20_GR_12 compared against 20 days of treatment against polymyxin B (PMB), colistin (CST)
691 or Octapeptin C4 (OctC4).

692 ^bMinimum Inhibitory Concentration tested for CST, Colistin; PMB, polymyxin B; OctC4, Octapeptin C4; AMX, Amoxicillin; ATM,
693 Aztreonam; FEP, Cefepime; CRO, Ceftriaxone; CHL, Chloramphenicol; CIP, Ciprofloxacin; GEN, Gentamicin; MEM, Meropenem;
694 PIP, Piperacillin; TET, Tetracycline; TGC, Tigecycline; TMP, Trimethoprim. Resistance determined as per CLSI guidelines and
695 EUCAST for tigecycline with: S, Susceptible; I, Intermediate; R, Resistant. Fluctuations in MIC values (n=4) are displayed by two letters
696 defining the resistance level. Resistance for Octapeptin C4 defined as ≥ 32 $\mu\text{g/ml}$.

TABLE 2 Detection of acquired resistance genes and plasmid replicons compared to the initial isolate and treatment groups

Strain ^a		Antibiotic class impacted ^b																Plasmids ^c						
		A				B						F	Q		S	T	Tr							
		<i>aac</i> (6')-Ib	<i>aph</i> (3')-Ia	<i>aph</i> (3'')-Ib	<i>aph</i> (6)-Id	<i>bla</i> KPC-2	<i>bla</i> KPC-9	<i>bla</i> LEN-12	<i>bla</i> OXA-9	<i>bla</i> SHV-12	<i>bla</i> TEM-1A	<i>bla</i> TEM-1B	<i>fosA</i>	<i>aac</i> (6')-Ib-cr	<i>oqxA</i>	<i>oqxB</i>	<i>sul2</i>	<i>tet</i> (A)	<i>df</i> rA14	I	II	III	IV	V
20 GR 12	2	2	2	2	2		2	2			2	2	2	2	2	2	2	2	2	2	2	2	2	2
CST_1	4	4	4	4	4		4	4		1	3	4	4	4	4	4	4	4	4	4	4	4	4	4
CST_2	4	4	4	4	4		4	4			4	4	4	4	4	4	4	4	4	4	4	4	4	4
CST_3	4	4	4	4	4		4	4			4	4	4	4	4	4	4	4	4	4	4	4	4	4
CST_4	4	4	4	4	4		4	4			4	4	4	4	4	4	4	4	4	4	4	4	4	4
PMB_1	4	4	4	4	4		4	4		1	3	4	4	4	4	4	4	4	4	4	4	4	4	4
PMB_2	4		4	4			4				4	4	4	4	4	4	4	4	4	4	4	4		
PMB_3	4	3	4	4	3		3	3	1		4	4	4	4	4	4	4	4	4	4	4	4	4	3
PMB_4	4	4	4	4	4		4	4		1	3	4	4	4	4	4	4	4	4	4	4	4	4	4
OctC4_1	4	4	4	4	1		3	4	1		4	4	4	4	4	4	4	4	4	4	4	4	4	4
OctC4_2	4	4			3		4	4		4		4	4	4	4					4	4	4		4
OctC4_3	4	4	2	2		4	3	4	1	2	2	4	4	4	4	2	2	2	4	4	4	2	4	
OctC4_4	4		1	1			4				1	4	4	4	4	1	1	1	4			1	4	

708 ^aStrain represents initial isolate (20_GR_12) and this strain subjected to 20 days of treatment with either colistin, CST; polymyxin B,
709 PMB; Octapeptin C4 and _replicate number.

710 ^bAcquired resistance genes as determined by ResFinder 2.1 ($\geq 90\%$ identity and $\geq 60\%$ length) for A, Aminoglycoside; B, Beta-Lactam;
711 F, Fosfomycin; Q, Quinolone; S, Sulfonamide; T, Tetracycline; Tr, Trimethoprim.

712 ^cPlasmid replicons detected by PlasmidFinder 1.3 ($\geq 95\%$ identity). Plasmid numbers represent I, ColRNAI; II, IncFIB(K)-Kpn3; III,
713 IncFII(K); IV, IncN; V, IncX3.

714 Shading represents the presence of the gene or plasmid and the number indicates the colonies harboring this attribute.

TABLE 3 Genomic alterations detected in day 20 resistance induced isolates

Strain ^a	Gene	Gene description	Nucleotide change ^b	Amino acid change ^c
CST_1(4)	<i>crrB</i>	Two-component hybrid sensor and regulator	A170T	D57V
CST_2(4)	<i>hepIII</i>	Lipopolysaccharide heptosyltransferase III	A238Δ ^{fs}	R80G ^{tr}
CST_2(4)	<i>mgrB</i>	Putative inner membrane protein	1-144Δ	1-47Δ
CST_3(4)	<i>mgrB</i>	Putative inner membrane protein	G3A	M1I
CST_3(4)	<i>phoQ</i>	Sensor protein	C1258G, G1300T	P420A, G434C
CST_4(3)	<i>epsJ</i>	Glycosyltransferase	T932G	L310STOP
CST_4(3)	<i>lptC</i>	Lipopolysaccharide export system protein	Δ498A ^{fs}	N166K ^{tr}
CST_4(4)	<i>mgrB</i>	Putative inner membrane protein	G-41T, A125T	N42I
CST_4(4)	<i>phoQ</i>	Sensor protein	G1249A	D417N
PMB_1(4)	<i>pmrB</i>	Sensor protein	C284T	P95L
PMB_2(4)	<i>dnaJ</i>	Chaperone protein	A892C	T298P
PMB_2(4)	<i>mgrB</i>	Putative inner membrane protein	G140T	W47L
PMB_2(4)	<i>phoP</i>	Transcriptional regulatory protein	C241T	R81C
PMB_2(4)	<i>hepIII</i>	Lipopolysaccharide heptosyltransferase III	TGAAGAGACCCG153Δ	Y51STOP
PMB_3(4)	<i>qseC</i>	Sensory histidine kinase	GCCTGAGCCTGC17Δ ^{fs} , A847C	S8R, I283L
PMB_4(4)	<i>mgrB</i>	Putative inner membrane protein	G85T	D29Y
PMB_4(4)	<i>qseC</i>	Sensory histidine kinase	CTGGATAAGCTG118Δ ^{fs}	L40F
PMB_4(4)	<i>yciM</i>	Lipopolysaccharide regulatory protein	T128G	V43G
OctC4_1(4)	<i>mlaD</i>	Uncharacterized ABC transporter, periplasmic component	C403T	Q135STOP
OctC4_1(4)	<i>pqiB</i>	Paraquat-inducible protein B	C1258T	Q420STOP
OctC4_1(4)	<i>traH</i>	Conjugal transfer protein	G417T	M139I
OctC4_2(4)	<i>pqiB</i>	Paraquat-inducible protein B	A2080C	T694P
OctC4_2(2)	<i>rpsA</i>	SSU ribosomal protein S1p	T1031A	L344Q
OctC4_3(2)	<i>hinT</i>	YcfF/hinT protein: purine nucleoside phosphoramidase	Δ240C ^{fs}	D81R ^{tr}
OctC4_4(2)	<i>azoR</i>	FMN-dependent NADH-azoreductase	T152A	L51Q
OctC4_2(4),3(4),4(4)	<i>mlaF</i>	Uncharacterized ABC transporter, ATP-binding protein	GCCGC493Δ ^{fs}	A165P ^{tr}

717 “Strain represented as treatment group (Colistin, CST; Polymyxin B, PMB; Octapeptin C4,
718 OctC4), _ replicate number and number of colonies impacted from the 4 selected.

719 ^bNucleotide variations present in ≥ 90 % of reads and ≥ 50 X coverage compared to initial strain,
720 20_GR_12. Δ symbolises a deletion, – in front of the nucleotide position indicates an alteration
721 upstream and ^{fs} represents a frameshift mutation.

722 ^cThe introduction of a truncation in the protein downstream of the alteration is noted as ^{tr}.